Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Cyclopentanohydrophenanthrene ring system doai
Reexamination Certificate
2005-11-15
2005-11-15
Badio, Barbara P. (Department: 1617)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Cyclopentanohydrophenanthrene ring system doai
C514S179000
Reexamination Certificate
active
06964953
ABSTRACT:
This invention generally pertains to the field of psychiatry. In particular, this invention pertains to the discovery that agents which inhibit the binding of cortisol to its receptors can be used in methods for treating stress disorders. Mifepristone, a potent specific glucocorticoid receptor antagonist, can be used in these methods. The invention also provides a kit for treating stress disorders in a human including a glucocorticoid receptor antagonist and instructional material teaching the indications, dosage and schedule of administration of the glucocorticoid receptor antagonist.
REFERENCES:
patent: 5447951 (1995-09-01), Politi et al.
patent: 6150349 (2000-11-01), Schatzberg et al.
patent: 6441015 (2002-08-01), Aspnes et al.
patent: 1 157 695 (2001-11-01), None
patent: WO 99/17779 (1999-04-01), None
patent: WO 00/54766 (2000-09-01), None
patent: WO 01/37840 (2001-05-01), None
Behl, C. et al., (1997), “Protection against oxidative stress-induced neuronal cell death-A novel role for RU486,”European J. of Neurosci., 9:912-920.
Heim, C. et al., (1999), “The potential role of hypocortisolism in the pathophysiology of stress-related bodily disorders,”Psychoneuroendocrinology, 25:1-25.
Sapolsky, R. et al., (1994), “The physiological relevance of glucocorticoid endangement of the hippocampus,”Ann NY Acad. Sci. 746:294-304.
Starkman, M. et al., (1999), “Decrease in cortisol reverses human hippocampal atrophy following treatment of Cushing's disease,”Biol Psychiatry, 46: 1595-1602.
Yedua, R., (2000), “Biology of posttraumatic stress disorder,”J Clin. Psychiarty, 61 Suppl 7(5):14-21.
Porter, N. et al., (1998), “Stress Hormone and Brain Aging: Adding Insult to Injury?,”Nature Neuroscience, 1:1, pp. 3-4.
Sapolsky, R., (2000), “Glucocorticoids and Hippocampal Atrophy in Neuropsychiatric Disorders,”Arch Gen Psychiatry, 57:925-935.
Cherkin et al., “Interruption by Halothane of Memory Consolidation in Chicks”,Fed. Proc., 24: 328 (1995).
Shors, “Acute Stress Rapidly and Persistently Enhances Memory Formation in the Male Rat”,Neurobiol. Learn. Mem. 75: 10-29 (2001).
Sandi et al., “Corticosteroid Receptor Antagonists are Amnestic for Passive Avoidance Learning in Day-old Chicks”,Euro. J. Neurosci. 6: 1292-1297 (1994).
Sandi et al., “Experience-dependent Facilitating Effect of Corticosterone on Spatial Memory Formation in the Water Maze”,Euro. J. Neurosci. 9: 637-642 (1997).
Van Der Lely, A.J., et al., “Rapid Reversal of Acute Psychosis in the Cushing Syndrome with the Cortisol-Receptor Antagonist Mitepristone (RU 486),”Annals of Internel Medicine, Jan. 15, 1991, pp. 143-144, vol. 114, No. 2, New York, NY.
Badio Barbara P.
Corcept Therapeutics, Inc.
LandOfFree
Methods for treating stress disorders using glucocorticoid... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods for treating stress disorders using glucocorticoid..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods for treating stress disorders using glucocorticoid... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3469296